Stillitano Francesca, Hansen Jens, Kong Chi-Wing, Karakikes Ioannis, Funck-Brentano Christian, Geng Lin, Scott Stuart, Reynier Stephan, Wu Ma, Valogne Yannick, Desseaux Carole, Salem Joe-Elie, Jeziorowska Dorota, Zahr Noël, Li Ronald, Iyengar Ravi, Hajjar Roger J, Hulot Jean-Sébastien
Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York, United States.
Department of Pharmacology and Systems Therapeutics, Systems Biology Center, Icahn School of Medicine at Mount Sinai, New York, United States.
Elife. 2017 Jan 30;6:e19406. doi: 10.7554/eLife.19406.
A large number of drugs can induce prolongation of cardiac repolarization and life-threatening cardiac arrhythmias. The prediction of this side effect is however challenging as it usually develops in some genetically predisposed individuals with normal cardiac repolarization at baseline. Here, we describe a platform based on a genetically diverse panel of induced pluripotent stem cells (iPSCs) that reproduces susceptibility to develop a cardiotoxic drug response. We generated iPSC-derived cardiomyocytes from patients presenting in vivo with extremely low or high changes in cardiac repolarization in response to a pharmacological challenge with sotalol. In vitro, the responses to sotalol were highly variable but strongly correlated to the inter-individual differences observed in vivo. Transcriptomic profiling identified dysregulation of genes (, ) involved in downstream regulation of cardiac repolarization machinery as underlying high sensitivity to sotalol. Our findings offer novel insights for the development of iPSC-based screening assays for testing individual drug reactions.
大量药物可导致心脏复极化延长及危及生命的心律失常。然而,预测这种副作用具有挑战性,因为它通常在一些基线时心脏复极化正常的遗传易感性个体中出现。在此,我们描述了一个基于基因多样化的诱导多能干细胞(iPSC)库的平台,该平台可重现发生心脏毒性药物反应的易感性。我们从体内对索他洛尔药理学激发试验表现出极低或极高心脏复极化变化的患者中生成了iPSC衍生的心肌细胞。在体外,对索他洛尔的反应高度可变,但与体内观察到的个体间差异密切相关。转录组分析确定参与心脏复极化机制下游调节的基因(,)失调是对索他洛尔高度敏感的基础。我们的发现为开发基于iPSC的筛选试验以测试个体药物反应提供了新的见解。